<p>2025 年 4 月 30 日- 下午 1:46</p>
<p>加利福尼亚州帕洛阿尔托，2025 年 4 月 30 日（环球新闻通讯社）-- Scilex Holding Company（纳斯达克代码：SCLX，“Scilex” 或 “公司”），是一家创新的创收公司，专注于收购、开发和商业化非阿片类疼痛管理产品，以治疗急性和慢性疼痛以及神经退行性和心代谢疾病，今天宣布已收到纳斯达克证券市场有限责任公司的通知，确认公司已重新符合纳斯达克上市规则 5550(a)(2) 下的最低收盘竞价要求。为了重新符合要求，公司必须在至少连续十个交易日内维持每股最低收盘竞价为 1.00 美元。该要求于 2025 年 4 月 30 日得到满足。</p>
<p>公司的普通股和公开认股权证将继续在纳斯达克资本市场交易，交易代码分别为 “SCLX” 和 “SCLXW”。</p>
<p>有关 Scilex Holding Company 的更多信息，请访问 www.scilexholding.com</p>
<p>有关 Semnur Pharmaceuticals, Inc.的更多信息，请访问 www.semnurpharma.com</p>
<p>有关 ZTlido®的更多信息，包括完整的处方信息，请访问 www.ztlido.com。</p>
<p>有关 ELYXYB®的更多信息，包括完整的处方信息，请访问 www.elyxyb.com。</p>
<p>有关 Gloperba®的更多信息，包括完整的处方信息，请访问 www.gloperba.com。</p>
<p>https://www.facebook.com/scilex.pharm</p>
<p>https://www.linkedin.com/company/scilex-holding-company/</p>
<p>info@scilexholding.com</p>
<p><strong>关于 Scilex Holding Company</strong></p>
<p>Scilex Holding Company 是一家创新的创收公司，专注于收购、开发和商业化非阿片类疼痛管理产品，以治疗急性和慢性疼痛以及神经退行性和心代谢疾病。Scilex 针对具有高未满足需求和大市场机会的适应症，致力于为急性和慢性疼痛患者提供非阿片类疗法，并致力于改善患者的治疗效果。Scilex 的商业产品包括：(i) ZTlido®（利多卡因局部系统）1.8%，一种由美国食品药品监督管理局（“FDA”）批准的处方利多卡因局部产品，用于缓解与带状疱疹后神经痛相关的神经性疼痛；(ii) ELYXYB®，一种潜在的一线治疗药物，是唯一获得 FDA 批准的即用型口服溶液，用于急性治疗成人偏头痛，无论是否伴有先兆；(iii) Gloperba®，首个也是唯一的液体口服版本的抗痛风药物秋水仙碱，适用于成人痛风发作的预防。</p>
<p>此外，Scilex 还有三个产品候选者：(i) SP-102（10 毫克，磷酸氟氯噻吨粘稠凝胶）（“SEMDEXA” 或 “SP-102”），一种新型的粘稠凝胶配方，广泛用于硬膜外注射以治疗腰骶根性疼痛或坐骨神经痛，Scilex 已完成第三阶段研究，并于 2017 年获得 FDA 的快速通道资格；(ii) SP-103（利多卡因局部系统）5.4%（“SP-103”），一种下一代三倍强度的 ZTlido 配方，用于急性疼痛的治疗，Scilex 最近已完成急性下背痛的第二阶段试验。SP-103 已获得 FDA 在下背痛方面的快速通道资格；(iii) SP-104（4.5 毫克，低剂量纳曲酮盐酸盐缓释胶囊）（“SP-104”），一种新型低剂量缓释纳曲酮盐酸盐，正在开发用于治疗纤维肌痛。</p>
<p>Scilex Holding Company 总部位于加利福尼亚州帕洛阿尔托。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿及在本新闻稿中讨论的事项的任何陈述均包含与 Scilex 及其子公司相关的前瞻性声明，依据 1995 年《私人证券诉讼改革法》第 21E 条的安全港条款，可能面临风险和不确定性，这可能导致实际结果与预测结果存在重大差异。前瞻性声明包括关于 Scilex 潜在开发和商业化肥胖、神经退行性、心代谢疾病治疗的声明。</p>
<p>可能导致 Scilex 实际结果与我们前瞻性声明中表达的结果存在重大不利差异的风险和不确定性包括但不限于：Scilex 保持符合纳斯达克持续上市要求的能力，以及维持公司证券在纳斯达克的上市；Scilex 开发和商业化肥胖症、神经退行性疾病、心代谢疾病治疗的能力；与交易市场的不确定性相关的风险，以及是否会为 Scilex 的普通股建立市场；一般经济、政治和商业环境；与 COVID-19（及其他类似干扰）相关的风险；Scilex 开发的潜在产品候选者可能无法按预期时间表推进临床开发或获得所需的监管批准的风险；与 Scilex 产品候选者的监管路径不确定性相关的风险；Scilex 可能无法成功营销或获得市场对其产品候选者的接受的风险；Scilex 的产品候选者可能对患者没有益处或未能成功商业化的风险；Scilex 可能高估了目标患者群体的规模、他们尝试新疗法的意愿以及医生开处方这些疗法的意愿的风险；SP-102、SP-103 或 SP-104 的试验和研究结果可能不成功或未能反映积极结果的风险；SP-102（SEMDEXA™）、SP-103 或 SP-104 的临床和研究者发起的试验的先前结果可能无法复制的风险；监管和知识产权风险；以及不时指出的其他风险和不确定性，以及在 Scilex 最近向证券交易委员会提交的定期报告中描述的其他风险，包括 Scilex 截至 2024 年 12 月 31 日的年度报告（Form 10-K）和随后提交的季度报告（Form 10-Q），包括这些文件中列出的风险因素。投资者被提醒不要过度依赖这些前瞻性声明，这些声明仅在本发布之日有效，Scilex 没有义务更新本新闻稿中的任何前瞻性声明，除非法律要求。</p>
<p><strong>联系方式：</strong></p>
<p>投资者和媒体</p>
<p>Scilex Holding Company</p>
<p>960 San Antonio Road</p>
<p>帕洛阿尔托，加利福尼亚州 94303</p>
<p>办公室： (650) 516-4310</p>
<p>电子邮件： investorrelations@scilexholding.com</p>
<p>网站： www.scilexholding.com</p>
<p>SEMDEXA™ (SP-102) 是 Semnur Pharmaceuticals, Inc.的商标，Semnur Pharmaceuticals, Inc.是 Scilex Holding Company 的全资子公司。计划进行 FDA 的专有名称审查。</p>
<p>ZTlido® 是 Scilex Pharmaceuticals Inc.的注册商标，Scilex Pharmaceuticals Inc.是 Scilex Holding Company 的全资子公司。</p>
<p>Gloperba® 是 Scilex Holding Company 拥有的注册商标的独占、可转让使用许可的主题。</p>
<p>ELYXYB® 是 Scilex Holding Company 拥有的注册商标。</p>
<p>所有其他商标均为其各自所有者的财产。</p>
<p>© 2025 Scilex Holding Company 保留所有权利。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRME1qQTFNaU0yT1RFME1qVXhJekl5TlRRM01qYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRME1qQTFNaU0yT1RFME1qVXhJekl5TlRRM01qYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzIyNGUzY2MtODc1My00NDg0LTg2ODUtMDRjYTU3YjZiNDZlLTEyNjYyNzYtMjAyNS0wNC0zMC1lbg==/tiny/Scilex-Holding-Company.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzIyNGUzY2MtODc1My00NDg0LTg2ODUtMDRjYTU3YjZiNDZlLTEyNjYyNzYtMjAyNS0wNC0zMC1lbg==/tiny/Scilex-Holding-Company.png"/></p>

SCLX

<p>Scilex Holding Company 已经重新符合纳斯达克的最低出价要求，截至 2025 年 4 月 30 日，连续十个交易日的收盘出价保持在每股 1.00 美元。该公司的普通股和公开认股权证将继续在纳斯达克资本市场交易，交易代码为 "SCLX" 和 "SCLXW"。Scilex 专注于非阿片类疼痛管理产品，并在其产品组合中拥有多个获得 FDA 批准的治疗方案和产品候选者</p>

<p>04/30/2025 - 01:46 PM</p>
<div class="lb-trans"><p>2025 年 4 月 30 日- 下午 1:46</p>
</div><p>PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least ten consecutive trading days. This requirement was met on April 30, 2025.</p>
<div class="lb-trans"><p>加利福尼亚州帕洛阿尔托，2025 年 4 月 30 日（环球新闻通讯社）-- Scilex Holding Company（纳斯达克代码：SCLX，“Scilex” 或 “公司”），是一家创新的创收公司，专注于收购、开发和商业化非阿片类疼痛管理产品，以治疗急性和慢性疼痛以及神经退行性和心代谢疾病，今天宣布已收到纳斯达克证券市场有限责任公司的通知，确认公司已重新符合纳斯达克上市规则 5550(a)(2) 下的最低收盘竞价要求。为了重新符合要求，公司必须在至少连续十个交易日内维持每股最低收盘竞价为 1.00 美元。该要求于 2025 年 4 月 30 日得到满足。</p>
</div><p>The Company’s common stock and public warrants will continue to trade on the Nasdaq Capital Market under the symbols “SCLX” and “SCLXW”, respectively.</p>
<div class="lb-trans"><p>公司的普通股和公开认股权证将继续在纳斯达克资本市场交易，交易代码分别为 “SCLX” 和 “SCLXW”。</p>
</div><p>For more information on Scilex Holding Company, refer to www.scilexholding.com</p>
<div class="lb-trans"><p>有关 Scilex Holding Company 的更多信息，请访问 www.scilexholding.com</p>
</div><p>For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com</p>
<div class="lb-trans"><p>有关 Semnur Pharmaceuticals, Inc.的更多信息，请访问 www.semnurpharma.com</p>
</div><p>For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.</p>
<div class="lb-trans"><p>有关 ZTlido®的更多信息，包括完整的处方信息，请访问 www.ztlido.com。</p>
</div><p>For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.</p>
<div class="lb-trans"><p>有关 ELYXYB®的更多信息，包括完整的处方信息，请访问 www.elyxyb.com。</p>
</div><p>For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.</p>
<div class="lb-trans"><p>有关 Gloperba®的更多信息，包括完整的处方信息，请访问 www.gloperba.com。</p>
</div><p>https://www.facebook.com/scilex.pharm</p>
<div class="lb-trans"><p>https://www.facebook.com/scilex.pharm</p>
</div><p>https://www.linkedin.com/company/scilex-holding-company/</p>
<div class="lb-trans"><p>https://www.linkedin.com/company/scilex-holding-company/</p>
</div><p>info@scilexholding.com</p>
<div class="lb-trans"><p>info@scilexholding.com</p>
</div><p><strong>About Scilex Holding Company</strong></p>
<div class="lb-trans"><p><strong>关于 Scilex Holding Company</strong></p>
</div><p>Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.</p>
<div class="lb-trans"><p>Scilex Holding Company 是一家创新的创收公司，专注于收购、开发和商业化非阿片类疼痛管理产品，以治疗急性和慢性疼痛以及神经退行性和心代谢疾病。Scilex 针对具有高未满足需求和大市场机会的适应症，致力于为急性和慢性疼痛患者提供非阿片类疗法，并致力于改善患者的治疗效果。Scilex 的商业产品包括：(i) ZTlido®（利多卡因局部系统）1.8%，一种由美国食品药品监督管理局（“FDA”）批准的处方利多卡因局部产品，用于缓解与带状疱疹后神经痛相关的神经性疼痛；(ii) ELYXYB®，一种潜在的一线治疗药物，是唯一获得 FDA 批准的即用型口服溶液，用于急性治疗成人偏头痛，无论是否伴有先兆；(iii) Gloperba®，首个也是唯一的液体口服版本的抗痛风药物秋水仙碱，适用于成人痛风发作的预防。</p>
</div><p>In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.</p>
<div class="lb-trans"><p>此外，Scilex 还有三个产品候选者：(i) SP-102（10 毫克，磷酸氟氯噻吨粘稠凝胶）（“SEMDEXA” 或 “SP-102”），一种新型的粘稠凝胶配方，广泛用于硬膜外注射以治疗腰骶根性疼痛或坐骨神经痛，Scilex 已完成第三阶段研究，并于 2017 年获得 FDA 的快速通道资格；(ii) SP-103（利多卡因局部系统）5.4%（“SP-103”），一种下一代三倍强度的 ZTlido 配方，用于急性疼痛的治疗，Scilex 最近已完成急性下背痛的第二阶段试验。SP-103 已获得 FDA 在下背痛方面的快速通道资格；(iii) SP-104（4.5 毫克，低剂量纳曲酮盐酸盐缓释胶囊）（“SP-104”），一种新型低剂量缓释纳曲酮盐酸盐，正在开发用于治疗纤维肌痛。</p>
</div><p>Scilex Holding Company is headquartered in Palo Alto, California.</p>
<div class="lb-trans"><p>Scilex Holding Company 总部位于加利福尼亚州帕洛阿尔托。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s potential development and commercialization of treatments for obesity, neurodegenerative, cardiometabolic disease.</p>
<div class="lb-trans"><p>本新闻稿及在本新闻稿中讨论的事项的任何陈述均包含与 Scilex 及其子公司相关的前瞻性声明，依据 1995 年《私人证券诉讼改革法》第 21E 条的安全港条款，可能面临风险和不确定性，这可能导致实际结果与预测结果存在重大差异。前瞻性声明包括关于 Scilex 潜在开发和商业化肥胖、神经退行性、心代谢疾病治疗的声明。</p>
</div><p>Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex’s ability to remain in compliance with the Nasdaq continued listing requirements and to maintain the listing of the Company’s securities thereon; Scilex’s ability to develop and commercialize treatments for obesity, neurodegenerative, cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.</p>
<div class="lb-trans"><p>可能导致 Scilex 实际结果与我们前瞻性声明中表达的结果存在重大不利差异的风险和不确定性包括但不限于：Scilex 保持符合纳斯达克持续上市要求的能力，以及维持公司证券在纳斯达克的上市；Scilex 开发和商业化肥胖症、神经退行性疾病、心代谢疾病治疗的能力；与交易市场的不确定性相关的风险，以及是否会为 Scilex 的普通股建立市场；一般经济、政治和商业环境；与 COVID-19（及其他类似干扰）相关的风险；Scilex 开发的潜在产品候选者可能无法按预期时间表推进临床开发或获得所需的监管批准的风险；与 Scilex 产品候选者的监管路径不确定性相关的风险；Scilex 可能无法成功营销或获得市场对其产品候选者的接受的风险；Scilex 的产品候选者可能对患者没有益处或未能成功商业化的风险；Scilex 可能高估了目标患者群体的规模、他们尝试新疗法的意愿以及医生开处方这些疗法的意愿的风险；SP-102、SP-103 或 SP-104 的试验和研究结果可能不成功或未能反映积极结果的风险；SP-102（SEMDEXA™）、SP-103 或 SP-104 的临床和研究者发起的试验的先前结果可能无法复制的风险；监管和知识产权风险；以及不时指出的其他风险和不确定性，以及在 Scilex 最近向证券交易委员会提交的定期报告中描述的其他风险，包括 Scilex 截至 2024 年 12 月 31 日的年度报告（Form 10-K）和随后提交的季度报告（Form 10-Q），包括这些文件中列出的风险因素。投资者被提醒不要过度依赖这些前瞻性声明，这些声明仅在本发布之日有效，Scilex 没有义务更新本新闻稿中的任何前瞻性声明，除非法律要求。</p>
</div><p><strong>Contacts:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Investors and Media</p>
<div class="lb-trans"><p>投资者和媒体</p>
</div><p>Scilex Holding Company</p>
<div class="lb-trans"><p>Scilex Holding Company</p>
</div><p>960 San Antonio Road</p>
<div class="lb-trans"><p>960 San Antonio Road</p>
</div><p>Palo Alto, CA 94303</p>
<div class="lb-trans"><p>帕洛阿尔托，加利福尼亚州 94303</p>
</div><p>Office: (650) 516-4310</p>
<div class="lb-trans"><p>办公室： (650) 516-4310</p>
</div><p>Email: investorrelations@scilexholding.com</p>
<div class="lb-trans"><p>电子邮件： investorrelations@scilexholding.com</p>
</div><p>Website: www.scilexholding.com</p>
<div class="lb-trans"><p>网站： www.scilexholding.com</p>
</div><p>SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.</p>
<div class="lb-trans"><p>SEMDEXA™ (SP-102) 是 Semnur Pharmaceuticals, Inc.的商标，Semnur Pharmaceuticals, Inc.是 Scilex Holding Company 的全资子公司。计划进行 FDA 的专有名称审查。</p>
</div><p>ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.</p>
<div class="lb-trans"><p>ZTlido® 是 Scilex Pharmaceuticals Inc.的注册商标，Scilex Pharmaceuticals Inc.是 Scilex Holding Company 的全资子公司。</p>
</div><p>Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.</p>
<div class="lb-trans"><p>Gloperba® 是 Scilex Holding Company 拥有的注册商标的独占、可转让使用许可的主题。</p>
</div><p>ELYXYB® is a registered trademark owned by Scilex Holding Company.</p>
<div class="lb-trans"><p>ELYXYB® 是 Scilex Holding Company 拥有的注册商标。</p>
</div><p>All other trademarks are the property of their respective owners.</p>
<div class="lb-trans"><p>所有其他商标均为其各自所有者的财产。</p>
</div><p>© 2025 Scilex Holding Company All Rights Reserved.</p>
<div class="lb-trans"><p>© 2025 Scilex Holding Company 保留所有权利。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RRME1qQTFNaU0yT1RFME1qVXhJekl5TlRRM01qYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTQ0MjA1MiM2OTE0MjUxIzIyNTQ3Mjc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YzIyNGUzY2MtODc1My00NDg0LTg2ODUtMDRjYTU3YjZiNDZlLTEyNjYyNzYtMjAyNS0wNC0zMC1lbg==/tiny/Scilex-Holding-Company.png" alt="" original-src="https://ml.globenewswire.com/media/YzIyNGUzY2MtODc1My00NDg0LTg2ODUtMDRjYTU3YjZiNDZlLTEyNjYyNzYtMjAyNS0wNC0zMC1lbg==/tiny/Scilex-Holding-Company.png"/></p>

Scilex 控股公司重新符合纳斯达克最低出价规则 | SCLX 股票新闻